Avenue Therapeutics, Inc. (ATXI) 是一家上市公司 属于 医疗保健 板块，经营于 生物科技 行业. 公司总部位于 New York City, NY, 美国. 现任CEO为 Alexandra MacLean.
ATXI 拥有 IPO日期为 2017-06-27, 2 名全职员工, 在 Other OTC, 市值为 $1.68M.
Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York.
